研 究 江苏省内券商牌照合并，增强长三角资源禀赋能力 ——东吴证券收购东海证券控制权点评 高超（分析师） 卢崑（分析师） gaochao1@kysec.cn 证书编号：S0790520050001 lukun@kysec.cn 证书编号：S0790524040002 2026 年 03 月 02 日 投资评级：看好（维持） 行业走势图 数据来源：聚源 -24% -12% 0% 12% 24% 36% 2025-03 2025-07 2025-11 证券Ⅱ 沪深300 相关研究报告 《指数化投资趋势延续，券商阵营和 蚂蚁增速领跑—2024H2 基金销售渠 道数据点评》-2025.3.16 事件：东吴证券 3 月 2 日公告，公司正在筹划通过发行 A 股股份的方式收购东 海证券股份有限公司控制权。公司 A 股股票将于 2026 年 3 月 2 日(星期一)开市 起停牌。 东吴证券拟收购东海证券控制权，属江苏同省不同市的券商牌照整合 2026 年 3 月 1 日，东吴证券拟通过发行股份的方式购买常投集团所持有的东海 证券 26.68%股权，以获得东海证券的控制权。东海证券实控人为常投集团（常 投集团股权结构为 90 ...

🚨JUST IN: STRATEGY BUYS 3,015 MORE BITCOIN, TOTAL STACK HITS 720,737 $BTCStrategy has added another 3,015 $BTC to its balance sheet, bringing total holdings to a staggering 720,737 $BTC.- Latest Purchase: 3,015 $BTC acquired for ~$204.1M at ~$67,700 per coin.- Total Holdings: 720,737 $BTC accumulated.- Total Investment: ~$54.77B spent at an average cost of ~$75,985 per $BTC. ...

A friend of mine has been a software engineer for 10 years$160k salary, gud company, stable lifeI told him a 13 year old on CT with 100k followers is making moreJust by copy pasting opinions of others about crypto every dayWithout a degree, no manager, no 9-5, no taxesHe told me "that's not a real job"Do you think i ragebaited him???i simply told him the truth kek ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年2月28日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 保集健康控股有限公司 呈交日期: 2026年3月2日 第 1 頁 共 10 頁 v 1.2.0 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01246 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 4,800,000,000 | HKD | | 0.25 | HKD | | 1,200,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 4,800,000,000 | HKD | | 0.25 | HKD | | ...

Latest: @APompliano’s ProCap Financial buys 450 $BTC, raising holdings to 5,457 $BTC and becoming the 19th largest public bitcoin holder. https://t.co/HCskD3WFTh ...

Michael Saylor(@saylor)'s @Strategy bought another 3,015$BTC($204.1M) at $67,700 last week.Strategy now holds 720,737 $BTC($47.45B) at an average price of $75,985, and is currently sitting on an unrealized loss of $7.32B (-13.36%).https://t.co/2XbrmAym6u ...

Trade together, earn together 🤝Invite friends, unlock fee savings for them, and collect rewards when you trade.More details: https://t.co/BvqmiWFu7l https://t.co/9un9P32961 ...

Group 1 - Jim Wyckoff has over 25 years of experience in stock, financial, and commodity markets, including roles as a financial journalist and reporter on commodity futures trading floors in Chicago and New York [1] - He has covered every futures market traded in the U.S. at various times throughout his career [1] - Jim is the owner of "Jim Wyckoff on the Markets," which provides analytical, educational, and trading advisory services [2] Group 2 - He has worked as a technical analyst for Dow Jones Newswires and as a senior market analyst with TraderPlanet.com [2] - Jim has also served as a consultant for the "Pro Farmer" agricultural advisory service and was the head equities analyst at CapitalistEdge.com [2] - He holds a degree in journalism and economics from Iowa State University [2]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準 確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產 生或因倚賴該等內容而引致之任何損失承擔任何責任。 CSPC PHARMACEUTICAL GROUP LIMITED 石 藥 集 團 有 限 公 司 石 藥 集 團 有 限 公 司（「 本 公 司 」， 連 同 其 附 屬 公 司 統 稱「 本 集 團 」）董 事 會（「 董 事 會 」）欣 然 宣 佈，本集團開發的注射用紫杉醇白蛋白納米粒（ 速溶型 ）(SYHX2011G1)（「該產品」）已獲得美 國食品藥品監督管理局(FDA)批准，可在美國開展臨床試驗。 乳腺癌是全球女性最常見的惡性腫瘤，嚴重危害女性的健康。紫杉烷類藥物是用於治療晚 期乳腺癌最常用且有效的細胞毒性化療藥物之一，無論是單獨治療還是聯合治療，均被證 明相較於其他類型的化療藥物有更顯著的生存獲益。該產品是採用專利技術開發的新一代 創新型納米製劑，有望成為全球首個速溶白蛋白結合型紫杉醇製劑。 本 次 獲 批 的 臨 床 適 應 症 為 治 療 聯 合 化 療 失 敗 的 轉 移 性 乳 腺 ...

Delivra Health encouraged by core business strength despite lower Q2 revenue Proactive uses images sourced from Shutterstock Delivra Health Brands Inc. (TSX-V:DHB, OTCQB:DHBUF, FRA:3F0) said it is encouraged by the strength of its core business fundamentals despite reporting lower revenue and wider adjusted losses in its second quarter. The Vancouver-based consumer health group posted net revenue of $2.433 million for the three months to 31 December 2025, down 12% from $2.754 million a year earlier. For ...